A real-world study on unmet medical needs in triptan-treated migraine: Prevalence, preventive therapies and triptan use modification from a large Italian population along two years

Carlo Piccinni, Sabina Cevoli, Giulia Ronconi, Letizia Dondi, Silvia Calabria, Antonella Pedrini, Immacolata Esposito, Valentina Favoni, Giulia Pierangeli, Pietro Cortelli, Nello Martini

Research output: Contribution to journalArticle

Abstract

Background: Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Italian population. Methods: A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4-9 triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10-14 triptan dose units per month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was analysed to describe the use of preventive therapies, the second year to describe the ≥50% reduction in triptan use. Results: Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2% were migraineurs with unmet medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month, 72.3% were affected by pLF-EM, 17.4% by pHF-EM, and 10.3% by pCM. In this cohort, 19.1% of individuals used oral preventive drugs and 0.1% botulinum toxin. Triptan use reduction was found in 22.3% individuals of the cohort, decreasing with the intensification of need levels (25.8% pLF-EM, 13.6% pHF-EM, 12.0% pCM). Conclusions: This real-life analysis underlined that the unmet medical needs concern a large part of patients treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows forecasting the actual impact of newest therapeutic strategies aimed to fill this gap.

Original languageEnglish
Article number74
JournalJournal of Headache and Pain
Volume20
Issue number1
DOIs
Publication statusPublished - Jun 27 2019

Fingerprint

Tryptamines
Migraine Disorders
Population
Therapeutics
Botulinum Toxins
varespladib methyl

Keywords

  • Administrative databases
  • Burden of disease
  • Italy
  • Observational study
  • Pharmacoepidemiology
  • Real-world evidence

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

A real-world study on unmet medical needs in triptan-treated migraine : Prevalence, preventive therapies and triptan use modification from a large Italian population along two years. / Piccinni, Carlo; Cevoli, Sabina; Ronconi, Giulia; Dondi, Letizia; Calabria, Silvia; Pedrini, Antonella; Esposito, Immacolata; Favoni, Valentina; Pierangeli, Giulia; Cortelli, Pietro; Martini, Nello.

In: Journal of Headache and Pain, Vol. 20, No. 1, 74, 27.06.2019.

Research output: Contribution to journalArticle

Piccinni, Carlo ; Cevoli, Sabina ; Ronconi, Giulia ; Dondi, Letizia ; Calabria, Silvia ; Pedrini, Antonella ; Esposito, Immacolata ; Favoni, Valentina ; Pierangeli, Giulia ; Cortelli, Pietro ; Martini, Nello. / A real-world study on unmet medical needs in triptan-treated migraine : Prevalence, preventive therapies and triptan use modification from a large Italian population along two years. In: Journal of Headache and Pain. 2019 ; Vol. 20, No. 1.
@article{5bc630af687b4eeab5515711206b9535,
title = "A real-world study on unmet medical needs in triptan-treated migraine: Prevalence, preventive therapies and triptan use modification from a large Italian population along two years",
abstract = "Background: Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Italian population. Methods: A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4-9 triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10-14 triptan dose units per month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was analysed to describe the use of preventive therapies, the second year to describe the ≥50{\%} reduction in triptan use. Results: Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2{\%} were migraineurs with unmet medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month, 72.3{\%} were affected by pLF-EM, 17.4{\%} by pHF-EM, and 10.3{\%} by pCM. In this cohort, 19.1{\%} of individuals used oral preventive drugs and 0.1{\%} botulinum toxin. Triptan use reduction was found in 22.3{\%} individuals of the cohort, decreasing with the intensification of need levels (25.8{\%} pLF-EM, 13.6{\%} pHF-EM, 12.0{\%} pCM). Conclusions: This real-life analysis underlined that the unmet medical needs concern a large part of patients treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows forecasting the actual impact of newest therapeutic strategies aimed to fill this gap.",
keywords = "Administrative databases, Burden of disease, Italy, Observational study, Pharmacoepidemiology, Real-world evidence",
author = "Carlo Piccinni and Sabina Cevoli and Giulia Ronconi and Letizia Dondi and Silvia Calabria and Antonella Pedrini and Immacolata Esposito and Valentina Favoni and Giulia Pierangeli and Pietro Cortelli and Nello Martini",
note = "Ricercatori distaccati presso IRCCS a seguito Convenzione esclusiva con Universit{\`a} di Bologna (Pierangeli Giulia, Cortelli Pietro).",
year = "2019",
month = "6",
day = "27",
doi = "10.1186/s10194-019-1027-7",
language = "English",
volume = "20",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - A real-world study on unmet medical needs in triptan-treated migraine

T2 - Prevalence, preventive therapies and triptan use modification from a large Italian population along two years

AU - Piccinni, Carlo

AU - Cevoli, Sabina

AU - Ronconi, Giulia

AU - Dondi, Letizia

AU - Calabria, Silvia

AU - Pedrini, Antonella

AU - Esposito, Immacolata

AU - Favoni, Valentina

AU - Pierangeli, Giulia

AU - Cortelli, Pietro

AU - Martini, Nello

N1 - Ricercatori distaccati presso IRCCS a seguito Convenzione esclusiva con Università di Bologna (Pierangeli Giulia, Cortelli Pietro).

PY - 2019/6/27

Y1 - 2019/6/27

N2 - Background: Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Italian population. Methods: A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4-9 triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10-14 triptan dose units per month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was analysed to describe the use of preventive therapies, the second year to describe the ≥50% reduction in triptan use. Results: Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2% were migraineurs with unmet medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month, 72.3% were affected by pLF-EM, 17.4% by pHF-EM, and 10.3% by pCM. In this cohort, 19.1% of individuals used oral preventive drugs and 0.1% botulinum toxin. Triptan use reduction was found in 22.3% individuals of the cohort, decreasing with the intensification of need levels (25.8% pLF-EM, 13.6% pHF-EM, 12.0% pCM). Conclusions: This real-life analysis underlined that the unmet medical needs concern a large part of patients treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows forecasting the actual impact of newest therapeutic strategies aimed to fill this gap.

AB - Background: Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Italian population. Methods: A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4-9 triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10-14 triptan dose units per month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was analysed to describe the use of preventive therapies, the second year to describe the ≥50% reduction in triptan use. Results: Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2% were migraineurs with unmet medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month, 72.3% were affected by pLF-EM, 17.4% by pHF-EM, and 10.3% by pCM. In this cohort, 19.1% of individuals used oral preventive drugs and 0.1% botulinum toxin. Triptan use reduction was found in 22.3% individuals of the cohort, decreasing with the intensification of need levels (25.8% pLF-EM, 13.6% pHF-EM, 12.0% pCM). Conclusions: This real-life analysis underlined that the unmet medical needs concern a large part of patients treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows forecasting the actual impact of newest therapeutic strategies aimed to fill this gap.

KW - Administrative databases

KW - Burden of disease

KW - Italy

KW - Observational study

KW - Pharmacoepidemiology

KW - Real-world evidence

UR - http://www.scopus.com/inward/record.url?scp=85068256215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068256215&partnerID=8YFLogxK

U2 - 10.1186/s10194-019-1027-7

DO - 10.1186/s10194-019-1027-7

M3 - Article

C2 - 31248360

AN - SCOPUS:85068256215

VL - 20

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 1

M1 - 74

ER -